Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin

Sarcoma

Volumn 2009, Issue , 2009, Pages

  Oosten, A W ^a   Seynaeve, C ^a   Schmitz, P I M ^a   Den Bakker, M A ^b   Verweij, J ^a   Sleijfer, S ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERUS MYOMA;

EID: 75149168385     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2009/348910     Document Type: Article

References (31)

1. Sleijfer S., Seynaeve C., Verweij J., Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care Oncologist 2005 10 10 833 841
2. Tascilar M., Loos W. J., Seynaeve C., Verweij J., Sleijfer S., The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas Oncologist 2007 12 11 1351 1360
3. Demetri G. D., von Mehren M., Blanke C. D., Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors The New England Journal of Medicine 2002 347 7 472 480
4. Sleijfer S., Wiemer E., Verweij J., Drug Insight: gastrointestinal stromal tumors (GIST)the solid tumor model for cancer-specific treatment Nature Clinical Practice Oncology 2008 5 2 102 111
5. van Oosterom A. T., Judson I., Verweij J., Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study The Lancet 2001 358 9291 1421 1423
6. Fata F., OReilly E., Ilson D., Paclitaxel in the treatment of patients with anglosarcoma of the scalp or face Cancer 1999 86 10 2034 2037
7. Penel N., Bui B. N., Bay J.-O., Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study Journal of Clinical Oncology 2008 26 32 5269 5274
8. Schlemmer M., Reichardt P., Verweij J., Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group European Journal of Cancer 2008 44 16 2433 2436
9. Grosso F., Jones R. L., Demetri G. D., Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study Lancet Oncology 2007 8 7 595 602
10. Toro J. R., Travis L. B., Wu H. J., Zhu K., Fletcher C. D. M., Devesa S. S., Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 19782001: an analysis of 26,758 cases International Journal of Cancer 2006 119 12 2922 2930
11. Edmonson J. H., Ryan L. M., Blum R. H., Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas Journal of Clinical Oncology 1993 11 7 1269 1275
12. Van Glabbeke M., van Oosterom A. T., Oosterhuis J. W., Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimensa European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study Journal of Clinical Oncology 1999 17 1 150 157
13. Verweij J., van Oosterom A., Blay J.-Y., Imatinib mesylate (STI-571 Glivec, GleevecTM) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study European Journal of Cancer 2003 39 14 2006 2011
14. Skubitz K. M., Skubitz A. P. N., Differential gene expression in leiomyosarcoma Cancer 2003 98 5 1029 1038
15. Hensley M. L., Blessing J. A., Mannel R., Rose P. G., Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial Gynecologic Oncology 2008 109 3 329 334
16. Therasse P., Arbuck S. G., Eisenhauer E. A., New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada Journal of the National Cancer Institute 2000 92 3 205 216
17. Therasse P., Le Cesne A., Van Glabbeke M., Verweij J., Judson I., RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma European Journal of Cancer 2005 41 10 1426 1430
18. Van Glabbeke M., Verweij J., Judson I., Nielsen O. S., Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas European Journal of Cancer 2002 38 4 543 549
19. Karavasilis V., Seddon B. M., Ashley S., Al-Muderis O., Fisher C., Judson I., Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients Cancer 2008 112 7 1585 1591
20. Baird K., Davis S., Antonescu C. R., Gene expression profiling of human sarcomas: insights into sarcoma biology Cancer Research 2005 65 20 9226 9235
21. vancrov L., Blay J. Y., Judson I. R., Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group European Journal of Cancer 2002 38 4 556 559
22. Von Burton G., Rankin C., Zalupski M. M., Mills G. M., Borden E. C., Karen A., Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma American Journal of Clinical Oncology 2006 29 1 59 61
23. Look K. Y., Sandler A., Blessing J. A., Lucci J. A. III, Rose P. G., Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study Gynecologic Oncology 2004 92 2 644 647
24. Merimsky O., Meller I., Flusser G., Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study Cancer Chemotherapy and Pharmacology 2000 45 2 177 181
25. Okuno S., Edmonson J., Mahoney M., Buckner J. C., Frytak S., Galanis E., Phase II trial of gemcitabine in advanced sarcomas Cancer 2002 94 12 3225 3229
26. Patel S. R., Gandhi V., Jenkins J., Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation Journal of Clinical Oncology 2001 19 15 3483 3489
27. Spth-Schwalbe E., Genvresse I., Koschuth A., Dietzmann A., Grunewald R., Possinger K., Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas Anti-Cancer Drugs 2000 11 5 325 329
28. Verweij J., Lee S. M., Ruka W., Randomized phase II study of docetaxel versus doxorubicin in first-and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Journal of Clinical Oncology 2000 18 10 2081 2086
29. Hensley M. L., Maki R., Venkatraman E., Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial Journal of Clinical Oncology 2002 20 12 2824 2831
30. Bay J.-O., Ray-Coquard I., Fayette J., Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis International Journal of Cancer 2006 119 3 706 711
31. Klimm B., Engert A., Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies Nature Clinical Practice Oncology 2008 5 6 316 323